Vivos Therapeutics (VVOS) Receivables - Net (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Receivables - Net data on file, last reported at $1.8 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $1.8 million, up 146.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 146.38% YoY), and the FY2025 annual result was $1.6 million, up 267.67% from the prior year.
• Receivables - Net grew to $1.8 million in Q1 2026 per VVOS's latest filing, from $1.6 million in the prior quarter.
• Over five years, Receivables - Net peaked at $2.1 million in Q3 2025 and troughed at $202000.0 in Q4 2023.
• A 5-year average of $813705.9 and a median of $525000.0 in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2022 and 2025: Receivables - Net sank 77.41% in 2022, then soared 370.04% in 2025.
• A 5-year view of Receivables - Net shows it stood at $457000.0 in 2022, then tumbled by 55.8% to $202000.0 in 2023, then surged by 112.87% to $430000.0 in 2024, then jumped by 267.67% to $1.6 million in 2025, then gained by 11.89% to $1.8 million in 2026.
• Business Quant data shows VVOS's Receivables - Net at $1.8 million in Q1 2026, $1.6 million in Q4 2025, and $2.1 million in Q3 2025.